As a GM-CSF inhibitor it will be mild side effects but possibly small amount developing blood pressure problems and blood clots. Where they may see problems in a phase 3 trial is that I doubt the FDA will let them get away with the same exclusion criteria and it will not be as effective in the actual serious cases as leronlimab. With leronlimab being the SOC the FDA will be looking for drugs better than us.